GBT News and Press, Global Blood Therapeutics Inc. From 08/10/22

NEW YORK, NY / ACCESSWIRE / August 10, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Global Blood Therapeutics, Inc. (N...

Global Blood Therapeutics press release ( NASDAQ: GBT ): Q2 GAAP EPS of -$1.26 misses by $0.08 . Revenue of $71.55M (+50.4% Y/Y) beats by $7.16M . Cash and cash equivalents of $261.15M For further details see: Global Blood Therapeutics GAAP EPS of -$1...

Pfizer Inc ( NYSE: PFE ) has executed a definitive merger agreement with Global Blood Therapeutics Inc ( NASDAQ: GBT ), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, ...

Trading in Global Blood Therapeutics (NASDAQ: GBT) stock was lively on Monday, with the blood-disorder-focused biotech rising by over 4% over Friday's close by midafternoon today. That's hardly surprising, as the company struck a deal to be acquired by one of the hottest operators i...

Pfizer will acquire Global Blood Therapeutics for $5.4 billion in cash or $68.50 per share. Pfizer is getting Oxbryta, a product with close to $300 million in annualized net sales and a decent pipeline focused on sickle cell disease. GBT601 has the potential to have improved effic...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Last week, Global Blood Therapeutics (NASDAQ: GBT ) stock was thrust into the spotlight on reports of a potential buyout bid from Pfizer (NYSE: PFE ). Today, though, Pfizer ...

Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell commu...

Pfizer ( NYSE: PFE ) has agreed to buy Global Blood Therapeutics ( GBT ) for $5.4B in cash, The Wall Street Journal reported on Monday citing people familiar with matter ahead of a formal announcement from the companies. According to the people, Pfizer is expected to...

Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...

The biotech industry for the first half of the year had seen better six-month periods in the past, but the situation appears to have changed beginning in July. From Jan. 1 to June 20, 2022, the SPDR S&P Biotech ETF ( XBI ) and iShares Nasdaq Biotechnology ETF ( IBB ) had...